All the news

Treatment with direct-acting antivirals (DAAs) reduced the risk of death, liver cancer and death from liver-related causes in French people with hepatitis C, according to results of one of the largest studies ...

Infection with HIV is associated with significantly worse survival for people with hepatocellular carcinoma (HCC, the most common type of primary liver cancer), according to findings from a large international cohort study published in ...

Nivolumab (Opdivo), a checkpoint inhibitor that helps the immune system fight cancer, was associated with tumour shrinkage or disease stabilisation in just over half of hepatocellular carcinoma (HCC) patients with substantial liver function ...

Taking aspirin about twice a week for five years or more may reduce the risk of developing hepatocellular carcinoma (HCC) by about half, according to research presented this week at the AASLD Liver ...

The US Food and Drug Administration last week granted accelerated approval for pembrolizumab (Keytruda), an immunotherapy drug known as a checkpoint inhibitor, for people with hepatocellular carcinoma (HCC). Over years or decades chronic hepatitis B ...

Ramucirumab (Cyramza), a type of targeted therapy that slows tumour growth by blocking blood vessel formation, led to improved overall survival and delayed disease progression in people with hepatocellular carcinoma ...

Personalised immunotherapy reduces the risk of liver cancer recurrence and may lead to tumour regression, according to a pair of studies presented at the 2018 International Liver Congress last month in Paris. In ...

Further research presented at this year’s International Liver Congress confirms that direct-acting antiviral (DAA) treatment leading to the cure of hepatitis C infection does not raise the risk of developing ...